|
- A phase 1, first-in-human, open label, escalation and expansion study . . .
ORM-5029 is a first-in-class human epidermal growth factor receptor 2 (HER2)-targeted antibody-drug conjugate (ADC) comprised of SMol006, a highly potent GSPT1 degrader, conjugated to pertuzumab, a clinically validated antibody
- Orum Therapeutics Announces First Patient Dosed In Phase 1 Clinical . . .
ORM-5029 is a first-in-class drug candidate designed to selectively deliver catalytic GSPT1 protein degraders to HER2-expressing tumor cells via antibody targeting
- Orum Ends ‘ORM-5029’, Advances New Candidate ‘ORM-1153’
Orum has discontinued further clinical development of ORM-5029, a HER2-targeted GSPT1 degrader-antibody conjugate (DAC) This decision follows an internal assessment of the program’s clinical progress and incorporates information previously disclosed
- Abstract 3933: ORM-5029: A first-in-class targeted protein degradation . . .
Here, we describe the development of ORM-5029, a highly potent and selective GSPT1 degrader targeting HER2-expressing tumor cells
- Study Details | Study of ORM-5029 in Subjects With HER2-Expressing . . .
This is a Phase 1 first-in-human study of ORM-5029 in participants with HER2-expressing advanced solid tumors The study consists of two parts: a Part 1 Dose Escalation and Part 2 Dose Expansion
- Orum shares plummet after termination of US breast cancer trial
Orum Therapeutics said it has voluntarily terminated the U S phase 1 clinical trial of its lead breast cancer candidate ORM-5029, sending its shares plummeting to the lower limit on the Kosdaq market
- Phase I Multicenter, Open-Label, First-in-Human Study of ORM-5029 in . . .
This is a Phase 1 first-in-human study of ORM-5029 in participants with HER2-expressing advanced solid tumors The study consists of two parts: a Part 1 Dose Escalation and Part 2 Dose Expansion
- Study of ORM-5029 in Subjects With HER2-Expressing Advanced Solid . . .
This is a Phase 1 first-in-human study of ORM-5029 in participants with HER2-expressing advanced solid tumors The study consists of two parts: a Part 1 Dose Escalation and Part 2 Dose Expansion
|
|
|